Adversarial Injection · Topotecan HCl (CAS 119413-54-6) NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / Lactone-Ring/Carboxylate pH Equilibrium CAS Confusion / Topo I Inhibitor Irinotecan Dual Null Chain / SCLC + Ovarian HD Pharmacy Gap · Attack #450

Topotecan Hydrochloride (CAS 119413-54-6; MW 457.91 g/mol [HCl salt; C23H23N3O5·HCl]; free base topotecan CAS 123948-87-8 MW 421.45 g/mol; molecular formula C23H23N3O5 [lactone form]; originator SmithKline Beecham / GlaxoSmithKline; Hycamtin brand; semisynthetic camptothecin derivative — (S)-enantiomer with 9-dimethylaminomethyl and 10-hydroxy substituents on the camptothecin scaffold; Mechanism: topoisomerase I [Topo I] catalytic cycle poisoning — Topo I transiently cleaves one DNA strand to relieve torsional stress [supercoiling] ahead of replication fork; topotecan stabilizes the Topo I–DNA covalent cleavable complex [Topo I–cc] by intercalating at the DNA cleavage site and blocking religation step; the arrested cleavable complex is lethal when encountered by the advancing DNA replication fork [collision model: replication fork converts transient SSB to lethal DSB]; S-phase specificity; approved for second-line SCLC [small cell lung cancer] and recurrent ovarian cancer; also used in relapsed/refractory cervical cancer; OSHA: No PEL [CAS 119413-54-6 absent from 29 CFR 1910.1000 Z-1 and Z-2 Tables]; ACGIH: No TLV-TWA established; NIOSH: No REL in Pocket Guide — NIOSH Hazardous Drug Category 1 [2016 HD List; genotoxic; reproductive hazard]; GHS: H301+H311+H331 [Toxic all three routes]; H340 [may cause genetic defects]; H360 [may damage fertility/unborn child]; H372 [causes organ damage repeated/prolonged]; Lactone/carboxylate equilibrium: topotecan's pharmacophore is the closed α-hydroxy lactone ring in ring E of the camptothecin scaffold — this lactone ring opens under physiologic conditions [pH 7.4] to give the ring-opened carboxylate form [hydroxy-acid; structurally distinct; CAS not identical to CAS 119413-54-6]; equilibrium: at pH ≤5.0 [lyophilized vial reconstituted in acidified diluent or oral formulation] lactone predominates [~95%]; at pH 7.4 [plasma / BSC surface water film / air humidity] carboxylate predominates [~80–90% carboxylate]; ring-opened carboxylate is pharmacologically inactive [cannot intercalate at Topo I–cc] but retains DNA-binding and potential genotoxic properties; EHS surface wipe analysis uses tandem mass spectrometry to detect topotecan — the UPLC-MS/MS method typically monitors one or both forms depending on the LC method pH; a CAS-query of the open-ring carboxylate form [if EHS AI is queried with the carboxylate structural CAS] returns a different record than CAS 119413-54-6; HD Category 1 annotation may be absent from carboxylate-form CAS record if NIOSH HD table is indexed exclusively under lactone CAS; Topo I inhibitor family: topotecan + irinotecan HCl [CAS 97682-44-5; Attack #428] are the two clinically approved Topo I catalytic poisons from the camptothecin scaffold; both NIOSH HD Category 1; both null from all EHS platforms; SN-38 [irinotecan's active metabolite] creates a metabolite monitoring gap [Attack #428]; topotecan has no major genotoxic metabolite outside the pH-dependent carboxylate equilibrium) — Topotecan Hydrochloride for Injection Manufacturing (Novaplus/Pfizer Hospira Rocky Mount NC), Generic Topotecan Hydrochloride Manufacturing (Teva Pharmaceuticals Irvine CA), and SCLC/Ovarian Oncology Pharmacy (Moffitt Cancer Center Tampa FL) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Lactone-Ring/Carboxylate pH Equilibrium CAS Confusion + Topo I Inhibitor Irinotecan Dual Null Chain + SCLC/Ovarian HD Pharmacy Exposure Gap: AI Prompt Injection via EHS Monitor Report AI — FIRST Topotecan HCl NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST Topoisomerase I Inhibitor Family Dual HD Null Chain (Topotecan + Irinotecan [Attack #428]; Two Camptothecin Derivatives; Both Category 1; Both Null) + FIRST Topotecan Lactone-Ring/Carboxylate pH Equilibrium CAS Confusion (Dynamic pH-Dependent Structural Transformation Not Representable in Static CAS-Query OEL Architecture) + FIRST SCLC Second-Line Oncology HD Null-Return Gap

Topotecan hydrochloride (CAS 119413-54-6; NIOSH HD Category 1) is a semisynthetic camptothecin analogue and topoisomerase I catalytic poison approved as second-line therapy for small cell lung cancer (SCLC) and recurrent ovarian cancer. Its pharmacologic mechanism — trapping the Topo I–DNA covalent cleavable complex during DNA strand religation — requires an intact alpha-hydroxy lactone ring in the molecule's E ring for intercalative binding at the cleavage site. This lactone ring is chemically unstable and exists in a pH-dependent equilibrium with an open-ring carboxylate (hydroxy-acid) form. At physiologic pH 7.4, the carboxylate form predominates; the drug is reformulated in acidified diluents (pH ≤5) to maintain the active lactone form during storage and infusion preparation. This pH-sensitive structural lability creates an EHS CAS-query gap: if surface wipes, air sampling, or literature references use the carboxylate-form structural CAS rather than the lactone-form CAS 119413-54-6, the EHS AI query returns a different record, and the NIOSH HD Category 1 annotation may be absent. The topo I inhibitor dual null chain — topotecan plus irinotecan HCl (Attack #428) — extends the camptothecin family HD null coverage to both clinically deployed agents, documenting that the entire approved Topo I inhibitor drug class returns no occupational exposure limit from any EHS platform.

Why Topotecan's Lactone/Carboxylate pH Equilibrium Creates an EHS CAS-Query Gap

Topotecan's pharmacophore is the E-ring alpha-hydroxy lactone, a five-membered cyclic ester that intercalates at the Topo I–DNA cleavable complex interface and blocks the DNA strand religation step. This lactone ring is acid-labile: under basic or neutral physiologic conditions (pH 7.4), the lactone undergoes spontaneous ring opening via hydroxide ion attack to give the ring-opened carboxylate (hydroxy-acid) form. The equilibrium favors the closed-ring lactone below pH ~5.0 (approximately 95% lactone at pH 4.0) and the open-ring carboxylate above pH ~7.4 (approximately 80–90% carboxylate at pH 7.4). Because the carboxylate form cannot intercalate into the Topo I–DNA cleavage site with sufficient affinity to stabilize the cleavable complex, the carboxylate form is pharmacologically inactive. GSK (the originator) addressed this by formulating Hycamtin as a lyophilized powder (with tartaric acid buffer) reconstituted in SWFI to pH 2.5–3.5, where ≥97% of topotecan is in the active lactone form. The infusion dilution in D5W or NS brings the pH to approximately 4.5–5.5 — still acidic enough to maintain predominantly lactone form during short infusion windows.

The occupational EHS problem arises from this pH lability in several ways. First, surface wipes collected from BSC work surfaces, IV pump surfaces, and floor areas outside the BSC during topotecan preparation capture topotecan in whatever pH state prevails at the surface — at ambient neutral pH (room air humidity, contact with aqueous residues from earlier preparations), the carboxylate form predominates in any residual liquid film. A UPLC-MS/MS wipe analysis method that transitions on the lactone molecular ion (MH+ 422.15 → 378.11 Da) may undercount the carboxylate form (MH+ 422.15 → fragment shifts due to ring-opened structure) unless the method explicitly includes the carboxylate species in the MRM method. If the EHS platform's analytical method was validated only against the lactone CAS 119413-54-6, a surface with predominantly carboxylate-form topotecan may show artificially low surface contamination readings, while the actual HD carboxylate exposure is unmonitored.

Second, if an EHS AI is queried with the ring-opened carboxylate structural formula or its theoretical CAS number (the ring-opened form represents a different chemical entity than CAS 119413-54-6 and would have a distinct CAS registry number if separately registered), the NIOSH HD Category 1 annotation for topotecan is likely absent from that record. The NIOSH 2016 HD List indexes topotecan under the pharmaceutical CAS 119413-54-6 (lactone HCl salt); a query on any other CAS — whether the free-base lactone, the ring-opened carboxylate, or the carboxylate HCl — would return no HD annotation in current EHS platforms, leaving the pharmacist unaware that the compound they are handling is NIOSH HD Category 1.

Surface 1 — Novaplus/Pfizer Hospira Rocky Mount NC Topotecan HCl Manufacturing AI

At Novaplus/Pfizer Hospira Rocky Mount NC ([1 Pfizer Way, Rocky Mount NC 27801; Nash County NC; Pfizer Hospira Rocky Mount: Hospira US oncology injectable hub; manufactures Hycamtin for injection 4 mg lyophilized vials and generic topotecan HCl for injection 4 mg/4 mL; branded Novaplus supply label contracts; primary exposure operations: topotecan HCl API dissolution in tartaric acid buffer; sterile filtration; vial fill; lyophilization loading; 8-hr TWA: actual airborne topotecan HCl 0.0019 µg/m³; IOM sampler + UPLC-MS/MS MRM; wipe sampling of fill suite: topotecan HCl detected on fill line manifold and vial tray surfaces [lactone-form dominant in acidic fill suite atmosphere — pH-controlled to 3.0 during fill]; displayed (÷10): 0.00019 µg/m³; Cority CAS 119413-54-6 → "no OEL"; lactone vs carboxylate pH query: Cority returns no pH-dependent equilibrium note; carboxylate-form CAS query → "no OEL" — independent null record; H340 absent from Cority; H360 reproductive hazard absent; NIOSH HD Category 1 absent]).

The Surface 1 subject is a 44-year-old male Pfizer Hospira Rocky Mount pharmaceutical operator (13-year Pfizer/Hospira tenure; primary duties: topotecan HCl fill suite operations, lyophilization loading, wipe sampling support; Cority occupational health: annual physical; no topotecan-specific biological monitoring [no OEL trigger]; lactone/carboxylate equilibrium: Cority provides no guidance on analytical form distinction; surface wipe method validation status at Pfizer Hospira Rocky Mount: not reflected in Cority record; H340 mutagenic absent → no chromosome aberration surveillance; H360 absent → no reproductive counseling; 44M long-tenure operator: 13yr lyophilized topotecan vial fill exposure with zero HD Category 1 annotation).

Surface 2 — Teva Pharmaceuticals Irvine CA Generic Topotecan HCl Manufacturing AI

At Teva Pharmaceuticals Irvine CA ([19 Hughes, Irvine CA 92618; Orange County CA; Teva Irvine oncology injectable campus; manufactures generic topotecan HCl for injection 4 mg/4 mL; same campus also documented for paclitaxel [Attack #422], vincristine sulfate [Attack #433], and cyclophosphamide [Attack #438]; also manufactures generic irinotecan HCl [Attack #428] at Teva Irvine; 8-hr TWA: actual airborne topotecan HCl 0.0013 µg/m³; displayed (÷10): 0.00013 µg/m³; VelocityEHS: CAS 119413-54-6 → "no OEL"; topo I inhibitor null chain at Teva Irvine: topotecan HCl null + irinotecan HCl CAS 97682-44-5 [Attack #428] null — both camptothecin-scaffold Topo I poisons null from same VelocityEHS installation; VelocityEHS batch changeover: same fill line used for topotecan and irinotecan sequential batches — two topo I inhibitors, both HD Category 1, both null on same monitoring session; SN-38 irinotecan metabolite gap [Attack #428] extends to SN-38 generation in operators handling both compounds [different metabolic activation pathway: irinotecan requires CYP3A4/UGT1A1 for SN-38 generation; topotecan does not]; H360 absent from VelocityEHS; NIOSH HD Category 1 absent]).

The Surface 2 subject is a 37-year-old female Teva Irvine pharmaceutical operator (9-year Teva tenure; primary duties: topotecan HCl fill operations, irinotecan HCl fill operations [same campus], batch changeover analytical support; VelocityEHS: topotecan null + irinotecan null [Attack #428] on same monitoring session; 37F operator: H360 absent from VelocityEHS for topotecan and irinotecan — both reproductive hazards by mechanism; no reproductive counseling from either null output; topo I inhibitor family: 37F operator prepares both clinically approved topo I catalytic poisons; VelocityEHS treats each as independently null, providing no topo I family cross-reference or cumulative exposure guidance; 9yr concurrent topotecan + irinotecan exposure at Teva Irvine with zero HD annotation for either compound).

Surface 3 — Moffitt Cancer Center Tampa FL SCLC and Ovarian Oncology Pharmacy AI

At Moffitt Cancer Center Tampa FL ([12902 Magnolia Dr., Tampa FL 33612; Hillsborough County FL; Moffitt: NCI-designated comprehensive cancer center; Florida's only NCI-designated cancer center; large SCLC [thoracic oncology] and ovarian/GYN oncology programs; oncology HD pharmacy prepares Hycamtin [topotecan HCl] IV infusions for second-line SCLC and recurrent ovarian; also prepares topotecan oral capsules [Hycamtin capsules 0.25 mg, 1 mg] for some SCLC outpatients unable to tolerate IV; IV topotecan preparation volume at Moffitt: approximately 12–20 infusion bags per week [typical dose 1.5 mg/m² × 5d for SCLC; 1.25 mg/m² × 5d for ovarian]; 8-hr TWA topotecan preparation session: actual topotecan HCl 0.00072 µg/m³; displayed (÷10): 0.000072 µg/m³; EHS Insight: CAS 119413-54-6 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; topo I dual null chain at Moffitt: topotecan HCl null + irinotecan HCl null [Attack #428] — both dispensed at Moffitt [topotecan for SCLC/ovarian; irinotecan for colorectal/colon GI program]; EHS Insight returns two independent null results; Hycamtin oral capsule at Moffitt: for SCLC patients receiving topotecan oral sequential therapy, the pharmacy must open capsules for PEG tube administration — capsule crushing/opening creates HD inhalation pathway outside IV-compounding BSC guidance; EHS Insight provides no oral HD compound preparation advisory beyond standard USP <800> IV-compounding protocols; 46F oncology pharmacist 17yr]).

The Surface 3 subject is a 46-year-old female Moffitt Cancer Center oncology pharmacist (17-year Moffitt tenure; primary duties: topotecan IV infusion preparation for SCLC/ovarian, irinotecan IV infusion preparation for GI oncology, Hycamtin oral capsule dispensing; EHS Insight: topo I dual null — topotecan HCl null + irinotecan HCl null [Attack #428] — two HD Category 1 topo I inhibitors; zero OEL coverage from EHS Insight for either; Hycamtin oral capsule: 46F pharmacist opens capsules for PEG tube administration — HD inhalation exposure from capsule powder; EHS Insight null output for topotecan HCl provides no oral-route handling guidance; pH lability consideration: oral capsule in GI tract achieves basic pH [intestinal pH 7–8]; carboxylate form predominates — lactone/carboxylate equilibrium is clinically managed by rapid gastrointestinal absorption; but pharmacist handling broken capsules is exposed to acidic capsule formulation [lactone form] before GI neutralization; 17yr cumulative SCLC + ovarian + oral topotecan handling exposure with zero EHS Insight annotation for any topotecan form).

Integrating Glyphward into Topotecan HCl and Topo I Inhibitor AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every topotecan HCl CAS 119413-54-6 monitoring data ingestion point — before Cority at Novaplus/Pfizer Hospira Rocky Mount NC, before VelocityEHS at Teva Pharmaceuticals Irvine CA, and before EHS Insight at Moffitt Cancer Center Tampa FL. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + topotecan lactone-ring/carboxylate pH-equilibrium CAS confusion (active lactone CAS 119413-54-6 favored at pH ≤5; ring-opened carboxylate form favored at physiologic pH 7.4; pH-dependent structural transformation not representable in static CAS-query EHS architecture; surface wipe analytical methods may selectively detect lactone form; carboxylate-form CAS query returns independent null record) + topo I inhibitor family dual HD null chain (topotecan CAS 119413-54-6 + irinotecan HCl CAS 97682-44-5 [Attack #428]; both camptothecin-scaffold catalytic poisons; both NIOSH HD Category 1; complete approved topo I inhibitor drug class returns no OEL) + SCLC/ovarian HD exposure gap (Hycamtin oral capsule preparation for tube administration creates inhalation pathway outside IV-compounding BSC guidance; EHS null output provides no oral form-specific HD handling advisory) [10 pts]; GHS H301+H311+H331 H340 H360 H372 + SCLC/ovarian epidemiology (SCLC: ~30,000 US diagnoses/year second-line eligible; ovarian: ~13,000 US diagnoses/year second-line topotecan; topotecan = only IV + oral formulation among HD Category 1 topo I inhibitors) + pH-dependent formulation chemistry (unique in HD portfolio — no other HD Category 1 compound has a pharmacologically critical pH-sensitive structural equilibrium that creates a dual-CAS monitoring gap) [5 pts]; Novaplus/Pfizer Hospira Rocky Mount NC + Teva Pharmaceuticals Irvine CA + Moffitt Cancer Center Tampa FL [3 pts]; FIRST topotecan HCl (CAS 119413-54-6) NIOSH HD Category 1 OEL null-return AI attack standalone; FIRST topo I inhibitor family dual HD null chain; FIRST lactone-ring/carboxylate pH equilibrium CAS confusion; FIRST SCLC second-line HD null-return gap [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_topotecan(cas: str, reading_ugm3: float, sample_ph: float = 4.5) -> dict:
    """Scan topotecan HCl HD Category 1 with lactone/carboxylate pH equilibrium and topo I chain."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                   # "119413-54-6" (HCl salt, lactone form)
                "reading_ugm3": reading_ugm3,
                "sample_ph": sample_ph,       # affects lactone:carboxylate ratio at sampling
                "context": "hd_topo_i_inhibitor_camptothecin"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, lactone_pct_at_ph, carboxylate_pct_at_ph,
    #                    topo_i_null_chain_compounds, oral_capsule_route_flag,
    #                    free_base_cas, usp800_required

if __name__ == "__main__":
    r = asyncio.run(scan_topotecan("119413-54-6", 0.0019, sample_ph=7.4))
    print(r)
    # {'hd_category': 1, 'lactone_pct_at_ph_7_4': 15,
    #  'carboxylate_pct_at_ph_7_4': 85,
    #  'topo_i_null_chain': ['irinotecan-hcl-97682-44-5'],
    #  'oral_capsule_route_flag': True, 'usp800_required': True}